Literature DB >> 9681392

Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.

V Bertrand1, S Quéré, R Guimbaud, P Sogni, L Chauvelot-Moachon, M Tulliez, D Lamarque, J Charreire, J P Giroud, D Couturier, S Chaussade, M Breban.   

Abstract

Rats transgenic for HLA-B27 and human beta 2-microglobulin develop a spontaneous, multisystem, inflammatory disease that resembles human B27-associated disease and that involves the gut mucosa. This model predominantly affects the colon and is characterized by an extensive infiltration of the mucosa by inflammatory cells, largely composed of mononuclear cells. In addition, an increased plasma level of nitric oxide (NO)-derived metabolites was described in this model. Deficiency in the anti-inflammatory cytokine, interleukin-10 (IL-10), leads to the development of colitis in IL-10 knockout mice, suggesting that IL-10 plays a major role in the control of gut inflammation. The objectives of this work were to study the mechanisms of the inflammatory bowel disease (IBD) in HLA-B27 rats and to determine the effects of treatment with IL-10. The 33-3 line of HLA-B27 recombinant rats with established disease was treated in two consecutive experiments with murine recombinant IL-10 for five weeks. Assessment of the effect of this treatment was performed, based on clinical, histological and biological (myeloperoxidase and inducible NO synthase activities; tumor necrosis factor-alpha, interferon-delta, CD3, iNOS and beta-actin mRNA expression. In 33-3 rats with established disease, mesenteric lymph nodes were hyperplastic, and colonic cellularity and MPO and iNOS activities in the colonic mucosa were increased without any detectable effects of IL-10 administration. IFN-gamma and iNOS mRNA were only detected in the colon of transgenic rats. Despite a lack of effect on disease expression, IL-10 strikingly reduced the level of IFN-gamma mRNA in gut mucosa. Up-regulation of IFN-gamma mRNA suggests that the IBD of HLA-B27 rats is mediated by T-helper 1 lymphocytes. Sustained administration of IL-10, in HLA-B27 rats with established disease, efficiently inhibited IFN-gamma mRNA expression but did not influence disease expression: these results indicate that IFN-gamma may exert a critical role at an earlier stage of the disease rather in the maintenance of the lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681392

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  8 in total

1.  Animal models of the spondyloarthropathies.

Authors:  M Breban; G Falgarone; H Blanchard; E Dernis-Labous; D Lamarque
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

2.  Attenuation of intestinal inflammation in interleukin-10-deficient mice infected with Citrobacter rodentium.

Authors:  Sara M Dann; Christine Le; Barun K Choudhury; Houpu Liu; Omar Saldarriaga; Elaine M Hanson; Yingzi Cong; Lars Eckmann
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

3.  Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis.

Authors:  Bi-Feng Qian; Susan L Tonkonogy; Frank Hoentjen; Levinus A Dieleman; R Balfour Sartor
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

4.  HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.

Authors:  Monica L DeLay; Matthew J Turner; Erin I Klenk; Judith A Smith; Dawn P Sowders; Robert A Colbert
Journal:  Arthritis Rheum       Date:  2009-09

5.  Interferon gamma downregulates IL-8 production in primary human colonic epithelial cells without induction of apoptosis.

Authors:  K Schlottmann; F-P Wachs; J Grossmann; D Vogl; M Maendel; W Falk; J Schölmerich; T Andus; G Rogler
Journal:  Int J Colorectal Dis       Date:  2004-02-21       Impact factor: 2.571

6.  TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats.

Authors:  Anna Franca Milia; Mirko Manetti; Sergio Generini; Lucia Polidori; Gemma Benelli; Marina Cinelli; Luca Messerini; Lidia Ibba-Manneschi; Marco Matucci-Cerinic
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

7.  Effects of a low-dose IL-2 treatment in HLA-B27 transgenic rat model of spondyloarthritis.

Authors:  L M Araujo; Q Jouhault; I Fert; I Bouiller; G Chiocchia; M Breban
Journal:  Arthritis Res Ther       Date:  2021-07-16       Impact factor: 5.156

8.  Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α.

Authors:  Anna Franca Milia; Lidia Ibba-Manneschi; Mirko Manetti; Gemma Benelli; Sergio Generini; Luca Messerini; Marco Matucci-Cerinic
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.